long intergenic non-protein coding RNA 2712Genealiases: []
Q-omics provides the consensus-scored LINC02712 profile across patient tissues and cancer cell-line models. LINC02712 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC02712 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LINC02712 RNA expression shows 16,698 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, KIRC, and PDAC as cancer lineages where LINC02712 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02712 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02712 survival associations across molecular data types. LINC02712 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02712 RNA expression–survival associations across cancer types. High LINC02712 expression shows unfavorable associations in LIHC, UVM and UCS, but favorable associations in LGG, SKCM and CHOL. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC02712 RNA expression.
This table summarizes LINC02712 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02712. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02712 shows lower tumor expression in LUSC, BRCA and BLCA and higher tumor expression in KIRC, THCA and KICH. The KIRC box plot shows higher LINC02712 RNA expression in tumor versus normal tissue (log2 FC = +0.386, t-test p < 0.001).
This table shows molecular features associated with LINC02712 in patient tissues and cancer cell lines. In patient samples, LINC02712 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
